Donanemab : New Alzheimer’s Drug A new Alzheimer’s drug, donanemab, has received support from an FDA advisory committee, moving closer to approval. Intended for early-stage Alzheimer’s, it shows significant slowing of cognitive decline. The drug works by targeting amyloid beta protein deposits in the brain. Alzheimer’s disease is a brain disorder that slowly destroys memory […]
